The combination of ATR and TOP1 inhibitors in STING‐low SCLC triggered activation of the STING‐IFN response and expression of pro‐inflammatory factors, and thus might transform “cold” tumors into “hot” tumors, which are more likely to respond to systemic immunotherapy. This evidence concerns the gene STING1 and small cell lung carcinoma.